Literature DB >> 30659125

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.

William G Wierda, John C Byrd, Jeremy S Abramson, Syed F Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A Chanan-Khan, Julio C Chavez, Steve E Coutre, Randall S Davis, Christopher D Fletcher, Brian Hill, Brad S Kahl, Manali Kamdar, Lawrence D Kaplan, Nadia Khan, Thomas J Kipps, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Vishala T Neppalli, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Mary A Dwyer, Hema Sundar.   

Abstract

Chronic lymphocytic leukemia (CLL) is generally characterized by an indolent disease course. Histologic transformation (also known as Richter's transformation) to more aggressive lymphomas, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, occurs in approximately 2% to 10% of patients and is associated with a poor prognosis. These NCCN Guidelines Insights discuss the recommendations for the diagnosis and management of patients with histologic transformation.
Copyright © 2019 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2019        PMID: 30659125     DOI: 10.6004/jnccn.2019.0002

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  17 in total

Review 1.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

2.  Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).

Authors:  Sonia Jaramillo; Andreas Agathangelidis; Christof Schneider; Jasmin Bahlo; Sandra Robrecht; Eugen Tausch; Johannes Bloehdorn; Manuela Hoechstetter; Kirsten Fischer; Barbara Eichhorst; Valentin Goede; Michael Hallek; Hartmut Döhner; Richard Rosenquist; Paolo Ghia; Kostas Stamatopoulos; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2019-12-26       Impact factor: 9.941

Review 3.  How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.

Authors:  Cecilia C S Yeung; Mazyar Shadman
Journal:  Curr Oncol Rep       Date:  2019-07-20       Impact factor: 5.075

4.  Chlorambucil-Iron Oxide Nanoparticles as a Drug Delivery System for Leukemia Cancer Cells.

Authors:  Samer Hasan Hussein-Al-Ali; Mohd Zobir Hussein; Saifullah Bullo; Palanisamy Arulselvan
Journal:  Int J Nanomedicine       Date:  2021-09-08

5.  PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.

Authors:  Christopher Ronald Funk; Shuhua Wang; Kevin Z Chen; Alexandra Waller; Aditi Sharma; Claudia L Edgar; Vikas A Gupta; Shanmuganathan Chandrakasan; Jaquelyn T Zoine; Andrew Fedanov; Sunil S Raikar; Jean L Koff; Christopher R Flowers; Silvia Coma; Jonathan A Pachter; Sruthi Ravindranathan; H Trent Spencer; Mala Shanmugam; Edmund K Waller
Journal:  Blood       Date:  2022-01-27       Impact factor: 25.476

6.  [Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].

Authors:  J J Gong; Q S Yin; M J Li; H Ai; Q Wang; L Chen; X D Wei; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-09-14

7.  Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?

Authors:  Antonio Cuneo; Robin Foà
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-03-01       Impact factor: 2.576

Review 8.  An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.

Authors:  Jared A Cohen; Riccardo Bomben; Federico Pozzo; Erika Tissino; Andrea Härzschel; Tanja Nicole Hartmann; Antonella Zucchetto; Valter Gattei
Journal:  Cancers (Basel)       Date:  2020-04-07       Impact factor: 6.639

9.  Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL) in Finland between 2005-2015 show improved survival over time.

Authors:  Vesa Lindström; Katja M Hakkarainen; Juha Mehtälä; Riho Klement; Amy Leval; Tiina M Järvinen
Journal:  Eur J Haematol       Date:  2019-07-25       Impact factor: 2.997

10.  Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.

Authors:  Kristo Marvyin; Eirik Brekka Tjønnfjord; Unni Mathilde Breland; Geir Erland Tjønnfjord
Journal:  BMJ Case Rep       Date:  2020-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.